PepGen Inc. (PEPG) stock
Close on Nov 11, 2026Market cap $364.31MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $364.31M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.53
- Dividend yield
- –
- Free cash flow yield
- -17.37%
Fundamentals
- Net income
- -$73.31M
- EPS, diluted
- -$1.07
- Free cash flow
- -$63.28M
- Book value per share
- $1.49
- Diluted shares
- 69M
Trading
- Next earnings
- Mar 3, 2027 (estimated, during market hours)
- Previous close
- $4.61
- Open
- $5.40
- Day's range
- $5.11 – $5.90
- Volume
- 16,011,180
- Average volume (20 days)
- 7,147,151
- Beta (5 years)
- 1.02
- 52-week range
- $1.31 – $7.80
- RSI (14 days)
- 83.6
- Volatility (1 year)
- 141.9%
- Relative volume
- 7.35×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PEPG | S&P 500 | Difference | PEPG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +100.8% | -2.4% | +103.2 pts | ||
| 3 months | +81.4% | -1.2% | +82.5 pts | ||
| Year to date | -19.2% | +12.3% | −31.5 pts | ||
| 1 year | +13.1% | +12.4% | +0.7 pts | ||
| 3 years | +36.3% | +78.8% | −42.5 pts | +10.9% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PepGen filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About PepGen
Pharmaceutical Preparations
PepGen Inc. is a clinical-stage biotechnology company that develops oligonucleotide therapeutics for severe neuromuscular and neurologic disorders. The company utilizes an Enhanced Delivery Oligonucleotide platform that conjugates cell-penetrating peptides with synthetic oligonucleotides to improve delivery into target cells and tissues, including skeletal and cardiac muscle. Its lead candidate, PGN-EDODM1, targets the underlying genetic defect of myotonic dystrophy type 1 by binding to toxic expanded RNA repeats to correct cellular splicing. Because the company has no approved commercial treatments, its therapeutic candidates are intended for patients living with myotonic dystrophy type 1.
Company profile, executives and historyPepGen stock: common questions
What is PepGen's stock price?
PEPG closed at $5.26 on Nov 11, 2026, up 14.10% on the day. Over the past 52 weeks it traded between $1.31 and $7.80.
What is PepGen's market cap?
PepGen was worth $364.31M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PEPG's P/E ratio?
PepGen lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.07), so it has no meaningful P/E ratio.
Does PepGen pay a dividend?
No. PepGen has not paid a cash dividend over the last twelve months.
When does PepGen report earnings next?
PepGen is expected to report Q4 FY2026 results on Mar 3, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PEPG stock performed over the past year?
Including dividends, PEPG returned +13.1% over the past year, against +12.4% for the S&P 500.
How many PEPG shares are sold short?
3M shares were sold short at the latest FINRA report, 8.55% of the float, or 2.8 days of average trading volume.
Who are PepGen's competitors?
Companies most similar to PepGen by business, industry and size include DYN, TRDA, LRMR, STOK, BNTC.
See a number that looks wrong?